Health insurance company Clover Health (NASDAQ: CLOV) reported Q3 2026 results topping the market’s revenue expectations, with sales up 52.9% year on year to $759.3 million. The company’s full-year revenue guidance of $2.99 billion at the midpoint came in 1% above analysts’ estimates. Its GAAP profit of $0.01 per share was $0.01 above analysts’ consensus estimates.

Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Clover Health delivered results ahead of Wall Street expectations in the third quarter, driven by robust membership growth and improved operational performance. Management credited its clinically focused AI technology, Clover Assistant, for enhancing care quality and enabling more efficient cost management across its physician network. CEO Andrew Toy highlighted that increased Clover Assistant engagement and a disciplined growth strategy contributed to higher gross profit and operating margin expansion. The company also benefited from favorable inpatient utilization trends and better-than-expected performance in its Part D prescription drug line.

Looking forward, Clover Health’s updated guidance is built on continued cohort maturation, expanding Clover Assistant coverage, and operating leverage as the membership base grows. Management emphasized the compounding impact of higher quality ratings, with the flagship PPO plan achieving five Stars for payment year 2028, supporting investment flexibility and member retention. CEO Andrew Toy stated that AI will play a central role in driving efficiency and better care outcomes, while CFO Clay Thornton pointed to the growing base of returning members and anticipated operating cost reductions as key to expected earnings growth in 2027 and beyond.

Key insights from management’s remarks

Management cited accelerated Clover Assistant engagement, strong retention, and a focus on core markets as major drivers of the quarter’s performance and future positioning.

• AI-driven care model: Management highlighted the role of Clover Assistant, its proprietary AI tool, in enabling earlier disease detection and proactive management of chronic conditions, which has contributed to improved clinical quality and reduced total cost of care. The company believes this differentiates its Medicare Advantage model and supports ongoing profitability improvements.
• Membership growth in core markets: The largest gains stemmed from New Jersey and Georgia, where Clover has the deepest physician networks and highest Clover Assistant coverage. Management explained that cohort economics are strongest in these states, reinforcing the strategy to focus resources on established markets rather than rapid expansion into newer geographies.
• Improved operational efficiency: CFO Clay Thornton noted that the adjusted SG&A (selling, general, and administrative expenses) ratio improved by 120 basis points compared to last year, reflecting fixed cost leverage as the company scales. Investments in AI-enabled operations and administrative automation are expected to further lower variable costs over time.
• Five-Star PPO milestone: The flagship PPO plan achieved a five-Star rating for payment year 2028, making it the largest such contract in the country. Management views this as critical for maintaining competitive plan designs and retaining members as cohorts mature, given additional flexibility in benefit design and marketing throughout the year.
• Favorable medical cost trends: Inpatient utilization continued to trend positively, while outpatient utilization was elevated but remained within expectations. Part D performance also exceeded initial projections, contributing to better gross profit per member across all cohorts.

Drivers of future performance

Clover Health’s outlook emphasizes member cohort maturation, continued improvements in operational efficiency, and the expanding impact of AI on care and administrative processes.

• Cohort maturation drives profitability: Management expects that as members progress from their first to subsequent years with Clover, per-member gross profit increases significantly. The company cited historical data showing gross profit improvements of $70 from year one to year two and $85 from year two to year three, with a growing portion of members now moving into these higher-value cohorts.
• AI and operational leverage: The company is increasingly applying AI to both clinical and non-clinical operations, aiming to reduce administrative costs as membership scales. Management believes that automating workflows and enhancing data-driven care recommendations will support sustained margin expansion and improve the overall member experience.
• Regulatory and competitive dynamics: While favorable Star Ratings provide competitive advantage and marketing flexibility, management noted ongoing regulatory uncertainty—such as the pending government appeal—and competitive shifts in the Medicare Advantage landscape, particularly plan exits and benefit repricing in core markets, as factors that could impact growth and strategy.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will be watching (1) the pace and breadth of Clover Assistant adoption across both new and existing members, (2) the impact of cohort maturation on gross profit and operating margin expansion, and (3) the competitive response to plan exits and new entrants in core markets like New Jersey and Georgia. Progress in automating administrative processes and any regulatory developments will also be key areas to monitor.

Clover Health currently trades at $4.66, in line with $4.67 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.